BioXcel Therapeutics (BTAI) Interest & Investment Income (2018 - 2026)
BioXcel Therapeutics (BTAI) posted Interest & Investment Income of $131000.0 for Q2 2026, down 37.91% on a QoQ basis from $211000.0 in Q1 2026, and down 43.04% year-over-year from $230000.0 in Q2 2025.
Powered by 
Analysis
BioXcel Therapeutics (BTAI) Interest & Investment Income (2018 - 2026) Analysis & Trends
BioXcel Therapeutics has reported Interest & Investment Income for 9 years, with the latest figure at $131000.0 in Q2 2026.
- On a quarterly basis, Interest & Investment Income fell 43.04% year-over-year to $131000.0 in Q2 2026; TTM through Jun 2026 was $899000.0, a 39.79% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 59.03% from the prior year.
- Interest & Investment Income was $131000.0 for Q2 2026 at BioXcel Therapeutics, down from $211000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $2.0 million in Q1 2023, with the low at $15000.0 in Q1 2022.
- Average Interest & Investment Income over 5 years is $677111.1, with a median of $492000.0 recorded in 2024.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income jumped 82200.0% in 2022, then slumped 70.54% in 2025.
- Over 5 years, Interest & Investment Income stood at $1.5 million in 2022, then tumbled by 36.34% to $946000.0 in 2023, then tumbled by 61.1% to $368000.0 in 2024, then dropped by 12.77% to $321000.0 in 2025, then plunged by 59.19% to $131000.0 in 2026.
- The last three Interest & Investment Income figures came in at $131000.0 (Q2 2026), $211000.0 (Q1 2026), and $321000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.05 Bn | 197.06 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.07 Bn | 177.90 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.15 Bn | 124.30 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 82.66 Bn | 74.67 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 61.74 Bn | 56.55 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 54.51 Bn | 49.37 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.05 Bn | 30.74 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.88 Bn | 29.88 Bn | 1.16 Mn | 36.92 Mn |
| 10 | BioXcel Therapeutics | 2.19 Mn | 2.19 Mn | 160,000.00 | 131,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 131,000.00 |
| Mar 31, 2026 | 211,000.00 |
| Dec 31, 2025 | 321,000.00 |
| Sep 30, 2025 | 236,000.00 |
| Jun 30, 2025 | 230,000.00 |
| Mar 31, 2025 | 279,000.00 |
| Dec 31, 2024 | 368,000.00 |
| Sep 30, 2024 | 616,000.00 |
| Jun 30, 2024 | 671,000.00 |
| Mar 31, 2024 | 947,000.00 |
| Dec 31, 2023 | 946,000.00 |
| Sep 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Mar 31, 2023 | 2.02 Mn |
| Dec 31, 2022 | 1.49 Mn |
| Sep 30, 2022 | 823,000.00 |
| Jun 30, 2022 | 204,000.00 |
| Mar 31, 2022 | 15,000.00 |
| Dec 31, 2021 | 46,000.00 |
| Sep 30, 2021 | 1,000.00 |